Enzyme-mediated drug-drug interactions: a review of

Drug-drug interaction induction physiologically-based pharmacokinetic modeling regulatory guidance reversible inhibition targeted protein degraders time-dependent inhibition trial design

Journal

Drug metabolism reviews
ISSN: 1097-9883
Titre abrégé: Drug Metab Rev
Pays: England
ID NLM: 0322067

Informations de publication

Date de publication:
26 Jul 2024
Historique:
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 26 7 2024
Statut: aheadofprint

Résumé

Enzyme-mediated pharmacokinetic drug-drug interactions can be caused by altered activity of drug metabolizing enzymes in the presence of a perpetrator drug, mostly

Identifiants

DOI: 10.1080/03602532.2024.2381021 PMID: 39057923
pubmed: 39057923
doi: 10.1080/03602532.2024.2381021
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-33

Auteurs

Jaydeep Yadav (J)

Department of Pharmacokinetics, Dynamics, Metabolism &Bioanalytics (PDMB), Merck & Co., Inc., Boston, MA, USA.

Benjamin J Maldonato (BJ)

Department of Nonclinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.

Joseph M Roesner (JM)

Department of Pharmacokinetics, Dynamics, Metabolism &Bioanalytics (PDMB), Merck & Co., Inc., Boston, MA, USA.

Ana G Vergara (AG)

Department of Pharmacokinetics, Dynamics, Metabolism &Bioanalytics (PDMB), Merck & Co., Inc., Rahway, NJ, USA.

Erickson M Paragas (EM)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, CA, USA.

Theresa Aliwarga (T)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, CA, USA.

Sara Humphreys (S)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, CA, USA.

Classifications MeSH